1.
Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD,
Westermark P (2018) Amyloid nomenclature 2018: recommendations by the International Society of
Amyloidosis
(ISA)
nomenclature
committee.
Amyloid
25(4)
215-219.
10.1080/13506129.2018.1549825
2.
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing Common
Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation
135(14) 1357-1377. 10.1161/CIRCULATIONAHA.116.024438
3.
Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet
387(10038) 2641-2654. 10.1016/S0140-6736(15)01274-X
4.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP,
Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio
M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG,
Linhart A (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC
Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42(16) 1554-1568.
10.1093/eurheartj/ehab072
5.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin Amyloid
13
Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 73(22) 2872-2891.
10.1016/j.jacc.2019.04.003
6.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K,
Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz
MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac
biomarkers and serum free light chain measurements. J Clin Oncol 30(9) 989-995.
10.1200/JCO.2011.38.5724
7.
Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, Thibodeau SN (1996) The
premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 101(4)
395-400. 10.1016/S0002-9343(96)00229-X
8.
Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis
presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med
165(12) 1425-1429. 10.1001/archinte.165.12.1425
9.
Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC (2016)
Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type
Transthyretin: A Prospective, Observational Cohort Study. Circulation 133(3) 282-290.
10.1161/CIRCULATIONAHA.115.018852
14
10.
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL,
Maleszewski JJ, Dispenzieri A (2016) Natural History of Wild-Type Transthyretin Cardiac
Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol 68(10)
1014-1020. 10.1016/j.jacc.2016.06.033
11.
Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, Nakamura
M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M (2012) Long-term survival after liver
transplantation in patients with familial amyloid polyneuropathy. Neurology 78(9) 637-643.
10.1212/WNL.0b013e318248df18
12.
Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J,
Kawanami T, Kato T, Yamamoto M, Sobue G (2012) Natural history of transthyretin Val30Met
familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol
Neurosurg Psychiatry 83(2) 152-158. 10.1136/jnnp-2011-301299
13.
Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, Lachmann HJ,
Hawkins PN, Pratt G, Committee B (2015) Guidelines on the management of AL amyloidosis. Br J
Haematol 168(2) 186-206. 10.1111/bjh.13155
14.
Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, Seward JB, Tajik AJ
(1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac
15
amyloidosis. J Am Coll Cardiol 16(5) 1135-1141. 10.1016/0735-1097(90)90545-z
15.
Swanton RH, Brooksby IA, Davies MJ, Coltart DJ, Jenkins BS, Webb-Peploe MM (1977)
Systolic and diastolic ventricular function in cardiac amyloidosis. Studies in six cases diagnosed with
endomyocardial biopsy. Am J Cardiol 39(5) 658-664. 10.1016/s0002-9149(77)80125-2
16.
Dubrey S, Pollak A, Skinner M, Falk RH (1995) Atrial thrombi occurring during sinus
rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 74(5)
541-544. 10.1136/hrt.74.5.541
17.
Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, Edwards WD, Gertz MA,
Klarich KW (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.
Circulation 119(18) 2490-2497. 10.1161/CIRCULATIONAHA.108.785014
18.
Siqueira-Filho AG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER (1981)
M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63(1)
188-196. 10.1161/01.cir.63.1.188
19.
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S (2007) Evaluation and
management
of
the
cardiac
10.1016/j.jacc.2007.08.028
amyloidosis.
Am
Coll
Cardiol
50(22)
2101-2110.
16
20.
Koyama J, Ray-Sequin PA, Davidoff R, Falk RH (2002) Usefulness of pulsed tissue
Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL
(primary) amyloidosis. Am J Cardiol 89(9) 1067-1071. 10.1016/s0002-9149(02)02277-4
21.
Palka P, Lange A, Donnelly JE, Scalia G, Burstow DJ, Nihoyannopoulos P (2002) Doppler
tissue echocardiographic features of cardiac amyloidosis. J Am Soc Echocardiogr 15(11) 1353-1360.
10.1067/mje.2002.125285
22.
Koyama J, Davidoff R, Falk RH (2004) Longitudinal myocardial velocity gradient derived
from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic
dysfunction. J Am Soc Echocardiogr 17(1) 36-44. 10.1016/j.echo.2003.09.014
23.
Perugini E, Rapezzi C, Reggiani LB, Poole-Wilson P, Branzi A, Henein MY (2005)
Comparison of ventricular long-axis function in patients with cardiac amyloidosis versus idiopathic
restrictive cardiomyopathy. Am J Cardiol 95(1) 146-149. 10.1016/j.amjcard.2004.08.084
24.
Tanaka H (2019) Utility of strain imaging in conjunction with heart failure stage
classification
for
heart
failure
patient
management.
Echocardiogr
17(1)
17-24.
10.1007/s12574-018-0408-2
25.
Tanaka H (2021) Efficacy of echocardiography for differential diagnosis of left ventricular
17
hypertrophy: special focus on speckle-tracking longitudinal strain. J Echocardiogr 19(2) 71-79.
10.1007/s12574-020-00508-3
26.
Gorcsan J, 3rd, Tanaka H (2011) Echocardiographic assessment of myocardial strain. J Am
Coll Cardiol 58(14) 1401-1413. 10.1016/j.jacc.2011.06.038
27.
Biering-Sorensen T, Biering-Sorensen SR, Olsen FJ, Sengelov M, Jorgensen PG,
Mogelvang R, Shah AM, Jensen JS (2017) Global Longitudinal Strain by Echocardiography Predicts
Long-Term Risk of Cardiovascular Morbidity and Mortality in a Low-Risk General Population: The
Copenhagen City Heart Study. Circ Cardiovasc Imaging 10(3) 10.1161/CIRCIMAGING.116.005521
28.
Stanton T, Leano R, Marwick TH (2009) Prediction of all-cause mortality from global
longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ
Cardiovasc Imaging 2(5) 356-364. 10.1161/CIRCIMAGING.109.862334
29.
Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH,
Thomas JD (2012) Relative apical sparing of longitudinal strain using two-dimensional
speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac
amyloidosis. Heart 98(19) 1442-1448. 10.1136/heartjnl-2012-302353
30.
Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Stork S, Beer M, Gaudron PD, Morbach
18
C, Knop S, Geissinger E, Ertl G, Bijnens B, Weidemann F (2013) Impact of regional left ventricular
function
on
outcome
for
patients
with
AL
amyloidosis.
PLoS
One
8(3)
e56923.
10.1371/journal.pone.0056923
31.
Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Stork S, Gaudron PD, Knop S, Ertl G,
Bijnens B, Weidemann F (2013) Effect of combined systolic and diastolic functional parameter
assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular
hypertrophy. Circ Cardiovasc Imaging 6(6) 1066-1072. 10.1161/CIRCIMAGING.113.000683
32.
Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, Vorobiof G (2017)
Cardiac Amyloidosis: Diagnosis and Treatment Strategies. Curr Oncol Rep 19(7) 46.
10.1007/s11912-017-0607-4
33.
Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A, Pellikka PA,
Villarraga HR (2017) Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of
2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. JACC
Cardiovasc Imaging 10(4) 398-407. 10.1016/j.jcmg.2016.04.008
34.
Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ,
Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ (2014) CMR-based
differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 7(2) 133-142.
19
10.1016/j.jcmg.2013.08.015
35.
Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G (1998) Contribution of
magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric
hypertrophic cardiomyopathy. Am Heart J 136(5) 824-830. 10.1016/s0002-8703(98)70127-9
36.
Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha
T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon
JC, Hawkins PN, Fontana M (2017) Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J
Am Coll Cardiol 70(4) 466-477. 10.1016/j.jacc.2017.05.053
37.
Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular
magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10(54.
10.1186/1532-429X-10-54
38.
Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA,
Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M (2010) Role of cardiac magnetic resonance
imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3(2) 155-164.
10.1016/j.jcmg.2009.09.023
39.
Wan K, Sun J, Yang D, Liu H, Wang J, Cheng W, Zhang Q, Zeng Z, Zhang T, Greiser A,
20
Jolly MP, Han Y, Chen Y (2018) Left Ventricular Myocardial Deformation on Cine MR Images:
Relationship to Severity of Disease and Prognosis in Light-Chain Amyloidosis. Radiology 288(1)
73-80. 10.1148/radiol.2018172435
40.
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V,
Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan
CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD,
Hawkins PN, Moon JC (2015) Prognostic Value of Late Gadolinium Enhancement Cardiovascular
Magnetic
Resonance
in
Cardiac
Amyloidosis.
Circulation
132(16)
1570-1579.
10.1161/CIRCULATIONAHA.115.016567
41.
Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S,
Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ,
Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC (2014) Native T1 mapping in
transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2) 157-165. 10.1016/j.jcmg.2013.10.008
42.
Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan
CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC (2013) Noncontrast T1 mapping
for
the
diagnosis
of
cardiac
10.1016/j.jcmg.2012.11.013
amyloidosis.
JACC
Cardiovasc
Imaging
6(4)
488-497.
21
43.
Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA,
Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M
(2019) Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC Cardiovasc Imaging
12(5) 810-819. 10.1016/j.jcmg.2018.02.006
44.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O,
Gillmore JD, Glaudemans A, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS,
Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart R,
Verberne HJ, Bourque JM (2019) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert
consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence
base
and
standardized
methods
of
imaging.
Nucl
Cardiol
26(6)
2065-2123.
10.1007/s12350-019-01760-6
45.
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD,
Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB,
Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T,
Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C,
Hawkins PN (2016) Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation
133(24) 2404-2412. 10.1161/CIRCULATIONAHA.116.021612
22
46.
Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T,
Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS (2016)
Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival
for
Patients
With
ATTR
Cardiac
Amyloidosis.
JAMA
Cardiol
1(8)
880-889.
10.1001/jamacardio.2016.2839
47.
Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, Riley SJ, Subramanya V,
Brown EE, Hopkins CD, Ononogbu S, Perzel Mandell K, Halushka MK, Steenbergen C, Jr.,
Rosenberg AZ, Tedford RJ, Judge DP, Shah SJ, Russell SD, Kass DA, Sharma K (2020)
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and
Prevalence of Cardiac Amyloidosis. JACC Heart Fail 8(9) 712-724. 10.1016/j.jchf.2020.04.007
48.
Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ,
Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P
(2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection
fraction. Eur Heart J 36(38) 2585-2594. 10.1093/eurheartj/ehv338
49.
Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J,
Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS (2017)
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe
23
aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38(38) 2879-2887.
10.1093/eurheartj/ehx350
50.
Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T,
Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M,
Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA
(2021) Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am
Coll Cardiol 77(2) 128-139. 10.1016/j.jacc.2020.11.006
51.
Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, Kwon JH, Paeng JC, Kim HK, Cheon GJ,
Kim YJ, Kim I, Yoon SS, Seo JW, Sohn DW (2015) 11C-Pittsburgh B PET imaging in cardiac
amyloidosis. JACC Cardiovasc Imaging 8(1) 50-59. 10.1016/j.jcmg.2014.09.018
52.
Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, Falk RH, Di Carli MF,
Dorbala S (2015) 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin
Amyloid
Deposits:
Autoradiography
Study.
Circ
Cardiovasc
Imaging
8(8)
10.1161/CIRCIMAGING.114.002954
53.
Law WP, Wang WY, Moore PT, Mollee PN, Ng AC (2016) Cardiac Amyloid Imaging with
18F-Florbetaben PET: A Pilot Study. J Nucl Med 57(11) 1733-1739. 10.2967/jnumed.115.169870
24
54.
Bandula S, White SK, Flett AS, Lawrence D, Pugliese F, Ashworth MT, Punwani S, Taylor
SA, Moon JC (2013) Measurement of myocardial extracellular volume fraction by using equilibrium
contrast-enhanced CT: validation against histologic findings. Radiology 269(2) 396-403.
10.1148/radiol.13130130
10.1148/radiology.13130130
55.
Oda S, Emoto T, Nakaura T, Kidoh M, Utsunomiya D, Funama Y, Nagayama Y, Takashio S,
Ueda M, Yamashita T, Tsujita K, Ando Y, Yamashita Y (2019) Myocardial Late Iodine Enhancement
and Extracellular Volume Quantification with Dual-Layer Spectral Detector Dual-Energy Cardiac CT.
Radiol Cardiothorac Imaging 1(1) e180003. 10.1148/ryct.2019180003
56.
Scully PR, Patel KP, Saberwal B, Klotz E, Augusto JB, Thornton GD, Hughes RK, Manisty
C, Lloyd G, Newton JD, Sabharwal N, Kelion A, Kennon S, Ozkor M, Mullen M, Hartman N,
Cavalcante JL, Menezes LJ, Hawkins PN, Treibel TA, Moon JC, Pugliese F (2020) Identifying
Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients. JACC Cardiovasc
Imaging 13(10) 2177-2189. 10.1016/j.jcmg.2020.05.029
Figure 1
Figure 2
ATTRwt-CM
Hypertrophic Cardiomyopathy
Aortic Stenosis
Parasternal long-axis view
Parasternal long-axis view
Parasternal long-axis view
Polar Plot Longitudinal Strain Mapping
Polar Plot Longitudinal Strain Mapping
Polar Plot Longitudinal Strain Mapping
GLS=14.2%
GLS=13.2%
GLS=8.9%
Figure 3
Figure 4
ATTRwt-CM
Parasternal long-axis view
IVST：16.1 mm
PWT：16.2 mm
Hypertrophic Cardiomyopathy
CMR T1 mapping
Native T1: 1506 ms
Parasternal long-axis view
IVST：16.8 mm
PWT：9.2 mm
CMR T1 mapping
Native T1: 1168 ms
Figure 5
Essential Hypertension
AL-CM
Echocardiography
99mTc-PYP scintigraphy
Echocardiography
IVST：12.8 mm
PWT：12.2 mm
Grade 0
IVST：20.1 mm
PWT：19.1 mm
ATTRwt-CM
99mTc-PYP scintigraphy
Grade 1
Echocardiography
IVST：17.2 mm
PWT：18.8 mm
99mTc-PYP scintigraphy
Grade 3
Figure 6
Echocardiography
• IVST: 12.2 mm
• PWT: 13.0 mm
• LVEDV: 34 mL
• LVESV: 8 mL
• LVEF: 75 %
• LAVI: 65 mL/m2
12-lead electrocardiogram
99mTc-PYP
scintigraphy
Grade 0
Figure 7
Echocardiography
Polar Plot Longitudinal Strain
Mapping
Doppler-derived LV diastolic filling
99mTc-PYP scintigraphy
e’
rA
• IVST: 11.8 mm
• PWT: 12.8 mm
• LVEDV: 69 mL
• LVESV: 22 mL
• LVEF: 69%
• LAVI: 42 mL/m2
Grade III LV diastolic dysfunction
• GLS=13.0%
• Relative apical longitudinal
strain=1.08
• Septal apical-to-basal
longitudinal strain=4.40
Grade 3
Figure 8
Echocardiography
• IVST: 12.9 mm
• PWT: 16.0 mm
• LVEDV: 72 mL
• LVESV: 31 mL
• LVEF: 57%
• LAVI: 42 mL/m2
• Peak V: 4.4 m/s
• Mean PG: 42 mmHg
• AVA: 0.70 cm2
Polar Plot Longitudinal Strain Mapping
• GLS=9.8%
• Relative apical longitudinal strain=1.21
• Septal apical-to-basal longitudinal strain=8.93
99mTc-PYP
scintigraphy
Grade 3
Figure 9
Echocardiography
• IVST: 12.4 mm
• PWT: 12.7 mm
• LVEDV: 90 mL
• LVESV: 55 mL
• LVEF: 39%
• LAVI: 88 mL/m2
• Peak V: 5.2 m/s
• Mean PG: 77 mmHg
• AVA: 0.36 cm2
Cardiac CT
• ECV=34%
99mTc-PYP
scintigraphy
Grade 2
...
論文の公開元へ
